The system was characterized by the fact that CEL, in addition to acting as an anticancer drug, promoted the translocation of Nur77 expressed by the loaded Nur77 gene to the mitochondria and converted Bcl‐2 from an anti‐apoptotic protein to a pro‐apoptotic protein, thereby increasing the sensitivity of Bcl‐2 overexpressing cancer cells to the drug and achieving synergistic enhancement of both the chemotherapy and gene therapy. Here, BCL2 is linked to cancer.